Seeking Alpha

Novo Nordisk (NVO -0.9%) slips after an FDA review of its basal insulin degludec gets postponed...

Novo Nordisk (NVO -0.9%) slips after an FDA review of its basal insulin degludec gets postponed yet again. The review was pushed back to November after being delayed once before in June, as the agency continues to seek outside experts for a review. Degludec is a long-lasting insulin drug designed to compete with Sanofi's (SNY +2.5%) similar product Lantus.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|